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Acinetobacter (A.) baumannii is a Gram-nega-
tive, aerobic, non-fastidious, oxidase-negative
opportunistic bacterial pathogen, which has
emerged as a major cause of nosocomial infections,
such as pneumonia (most often ventilator-associated
pneumonia, VAP), infections of the bloodstream,
urinary tract, surgical sites or others occurring espe-
cially in intensive care units, critically ill or
immunocompromised patients (1, 2).
Recently, an increasing number of clinically
significant A. baumannii infections has been
observed worldwide. The most important features of
the bacterium are: the ability to prolonged survival in
the hospital environment, a high degree of genome
plasticity and, as a result, ability to rapidly acquire
resistance determinants. During the last decades, A.
baumannii resistance to most or all antimicrobial
agents available for therapeutic use, has been
observed. The percentage of strains non-susceptible
to carbapenems, that until recently were considered
as antibiotics of last-resort, increased. The carbapen-
em resistance phenotype has become increasingly
prevalent or even (in some regions) dominant (3, 4). 
Due to the increasing resistance, a group of
international experts, through an initiative of the
European Centre for Disease Prevention and Control
and the Centers for Disease Control and Prevention,
introduced terminology clearly defining multidrug-
resistant (MDR), extensively drug-resistant (XDR)
and pandrug-resistant (PDR) phenotypes of clinical-
ly relevant bacterial species. MDR was defined as
acquired non-susceptibility to at least one antimicro-
bial agent in three or more antimicrobial categories,
described by Magiorakos et al. (5). This definition
covers different bacterial species, including
Acinetobacter, of epidemiological significance,
increasing antimicrobial resistance and importance
within the healthcare system.
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Abstract: Acinetobacter baumannii is a major cause of nosocomial infections worldwide. Therapeutic options
in management of this bacteria are limited. Tigecycline is considered as an alternative treatment of infections
caused by multidrug-resistant A. baumannii strains, however this resistance has emerged recently. Another
growing problem is a lack of international consensus between U.S. FDA and EUCAST recommendations,
regarding tigecycline breakpoints for Acinetobacter spp., and frequently off-label use. The aim of the present
study was to assess the in vitro susceptibility to tigecycline and other antimicrobials, routinely used in the treat-
ment of infections, among 155 A. baumannii isolates, collected between 2008-2013 from a hospital in Poland.
The most active agent against the tested MDR strains was colistin (99.3% susceptible isolates). Our study has
shown a low efficiency of tigecycline, with 74.2% of non-susceptible strains (according to the U.S. FDA guide-
lines). Tigecycline MIC values ranged from 0.125 to 48 mg/L. The MIC50 and MIC90 were 3 and 8 mg/L,
respectively, and 25.8% (40) of the isolates displayed MIC = 2 mg/L. The highest percentage of tigecycline-
resistant strains were noted in 2010 (56.3%). Our study revealed remarkably high tigecycline non-susceptibili-
ty rates among MDR A. baumannii isolates, therefore this antimicrobial should be administered with caution.
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Isolation of strains resistant to all antimicrobial
agents available for the treatment, limits therapeutic
options and causes high mortality of patients with
Acinetobacter infections (6). Colistin remains active
against the MDR strains of A. baumannii, although
resistance to this agent has also been reported (7, 8).
Tigecycline, belonging to a new class of antimicro-
bials, known as glycylcyclines, is an alternative
antimicrobial to treat infections caused by the MDR
A. baumannii, however resistance to this drug in A.
baumannii is a rising problem (9). This agent pos-
sesses bacteriostatic activity against Gram-negative
bacilli, nevertheless the susceptibility breakpoint for
Acinetobacter spp. has not been adequately deter-
mined.
The mechanism of action of this derivative of
minocycline is based on reversible binding to the
30S subunit of the bacterial ribosome, which
inhibits the synthesis of amino acids. Tigecycline
shows broad-spectrum activity against Gram-posi-
tive and Gram-negative bacteria, anaerobes and
atypical bacteria as well as difficult-to-treat
pathogens, such as methicillin-resistant Staphylo-
coccus aureus (MRSA), vancomycin-resistant En-
terococcus spp., penicillin-resistant Streptococcus
pneumoniae, MDR Acinetobacter baumannii, and
Gram-negative bacterial strains that produce extend-
ed-spectrum β-lactamases (ESBL) (9). Minimal
organ toxicity and lack of dosage adjustment in most
patients are important considerations for use of this
compound in infection therapy (10).
Tigecycline was initially approved by the U.S.
Food and Drug Administration (FDA) in 2005, and
by the European Medicines Agency in 2006 for the
treatment of adults with complicated intra-abdominal
infections and complicated skin and skin structure
infections. In 2008, tigecycline also received FDA
approval for the treatment of adult patients with com-
munity-acquired bacterial pneumonia (11). The
clearest applications of tigecycline are for on-label
indications, but it could be also used to treat other
infections caused by multidrug-resistant pathogens.
Other clinical applications for tigecycline, not cur-
rently approved by the FDA, include: hospital-
acquired or ventilator-associated pneumonia, diabet-
ic foot infections, nosocomial urinary tract infec-
tions, and bloodstream infections (10, 12, 13).
The level of resistance of A. baumannii to tige-
cycline in various regions of the world differs with
the highest rates of non-susceptibility noted in MDR
strains (9). In case report studies many investigators
underline evolution and acquiring of resistance to
tigecycline by strains recovered from patients during
long-term tigecycline monotherapy (4, 14, 15).
The increasing number of serious infections
caused by MDR A. baumannii prompted the search
of a new class of antimicrobial agents as an alterna-
tive to medication with carbapenems and colistin,
and as a drug of last-resort, because in the nearest
future no treatment options may exist (10, 16).
The mechanism of rapid development of
tigecycline resistance among MDR A. baumannii
strains is poorly understood. Tigecycline non-sus-
ceptibility observed in Acinetobacter spp. clinical
isolates has been associated with up-regulation of
chromosomally encoded multidrug efflux system,
AdeABC, belonging to the resistance-nodulation-
cell division (RND) family of transporters (15,
17). The expression of the pump is regulated by
two-component system, containing a sensor
kinase (AdeS) and a response regulator (AdeR),
encoded by the adeRS operon. Overexpression
may be responsible for reducing accumulation of
many antimicrobials, including aminoglycosides,
fluoroquinolones, β-lactams, macrolides, chlor-
amphenicol, tetracycline, trimethoprim, and tige-
cycline. Overexpression of the AdeABC efflux
system can be caused by the therapeutic use of
tigecycline or other antibiotics. Molecular mecha-
nism of overexpression may be related to the
ISAba-1 insertion upstream of the adeABC oper-
on, or by point mutations in adeR and adeS genes
(10, 18). 
Due to the growing tigecycline resistance,
monitoring of its activity against A. baumannii is
crucial. Both global and local level surveillance,
using reference and commercial methods (e.g., disk
diffusion, Etest), may provide important insights
into the activity of tigecycline (19). 
The aim of the study was to assess the in vitro
susceptibility of A. baumannii clinical isolates to
tigecycline (Etest method) and to other antimicro-
bials (automated method), routinely used in the
treatment of infections. A. baumannii strains were
isolated from patients hospitalized in Krakowís hos-
pital, Poland between 2008 and 2013.
MATERIALS AND METHODS
Patients and bacterial strains
The study was conducted at the Ludwik
Rydygier Memorial Specialized Hospital, 700-bed,
tertiary care medical center in Krakow, Poland. A
total of 155 MDR A. baumannii clinical strains were
collected from patients hospitalized in different
wards of this medical center between 2008 and
2013. In particular years, various numbers of iso-
lates were recovered: in 2008 ñ 15 strains, i.e. 9.7%
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of the total number (155) of the examined A. bau-
mannii isolates, in 2009 ñ 74 (47.7%), 2010 ñ 16
(10.3%), 2011 ñ 17 (11.0%), 2012 ñ 10 (6.5%) and
in 2013 ñ 23 (14.8%) strains, respectively. Each
strain was isolated from another patient. Multi-sus-
ceptible A. baumannii strains were not included to
the study.
The patients enrolled in this study were treated
in the following hospital units: intensive care (86;
55.5%), burn therapy (39; 25.1%), orthopedic (11;
7.1%), surgical (6; 3.9%), and others, comprising:
neurology (3; 2.0%), plastic surgery (3; 2.0%), urol-
ogy (2; 1.4%), hematology (1; 0.6%), cardiology (1;
0.6%), toxicology (1; 0.6%), oncology (1; 0.6%)
and nephrology (1; 0.6%). Data recorded for each
patient included age, sex, and type of clinical speci-
men. The mean patient age was 56.6 years (from 15
to 100) and 117 (75.5%) of patients were male,
while 38 (24.5%) were female. Endotracheal aspi-
rates (ETAs) (74; 47.7%; ), wound swabs (31;
20.0%), blood samples (27; 17.4%), urine (17;
11.0%) and catheters (6; 3.9%) were the source of
isolates. Quantitative cultures were performed for
ETA and urine. Growth > 105 CFU/mL was taken as
the threshold for microbiological diagnosis of VAP,
while growth > 104 CFU/mL was taken as the cut-off
for urine. The information concerning clinical data
(e.g., antimicrobial treatment) of patients was
unavailable. 
Susceptibility testing methods
All the isolates were identified using Vitek 2
Compact system (bioMÈrieux, France). Identifi-
cation was confirmed by the species-specific PCR
for the blaOXA-51-like gene (20). 
Antimicrobial susceptibility testing with deter-
mination of minimal inhibitory concentration (MIC)
values for imipenem, meropenem, amikacin, gen-
tamicin, tobramycin, ciprofloxacin and colistin was
performed by using Vitek 2 Compact semiquantita-
tive automatic system (susceptibility cards used in
the study do not contain tigecycline) and interpreted
according to CLSI breakpoints (21). 
The susceptibility of A. baumannii isolates to
tigecycline was determined by using the quantitative
Etest method (bioMÈrieux, France), which measured
the MIC value of the antimicrobial agent. For this
purpose, the colonies from a 18-hour culture of A.
baumannii on solid medium were suspended in
0.85% NaCl solution in order to obtain an equiva-
lent of 0.5 McFarland units. The bacterial suspen-
sion was inoculated onto Mueller-Hinton 2 agar
(bioMÈrieux, France). EtestÆ TGC (TGC ñ tigecy-
cline) gradient stripes (0.016 to 256 mg/L) were
placed on the agar and incubated in aerobic condi-
tions in accordance with the manufacturerís recom-
mendations. 
Quality control was performed using
Escherichia coli ATCC 25922 and Pseudomonas
aeruginosa ATCC 27853 reference strains.
Tigecycline interpretative breakpoints for A. bau-
mannii
The U.S. FDA did not approve the interpreta-
tive criteria of tigecycline for A. baumannii in vitro
susceptibility testing, therefore the FDA recommen-
dations of tigecycline breakpoints used for
Enterobacteriaceae (susceptible, MIC = 2 mg/L;
intermediate, MIC > 2 or < 8 mg/L; resistant, MIC =
8 mg/L) were applied as MIC interpretation criteria
for A. baumannii (22-24).
According to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
expert rules the evidence that A. baumannii is a good
Table 1. Antimicrobial susceptibility of 155 Acinetobacter baumannii isolates with MIC50 and MIC90 values.
Antimicrobial agent No. (%) of isolates MIC [mg/L]
R I S 50% 90%
Imipenem 141 (91.0) 2 (1.3) 12 (7.7) ≥ 16 ≥ 16
Meropenem 144 (92.9) 1 (0.6) 10 (6.5) ≥ 16 ≥ 16
Amikacin 62 (40.0) 32 (20.6) 61 (39.4) 16 ≥ 64
Gentamicin 138 (89.0) 4 (2.6) 13 (8.4) ≥ 16 ≥ 16
Tobramicin 62 (40.0) 60 (38.7) 33 (21.3) 8 ≥ 16
Ciprofloxacin 155 (100.0) 0 (0) 0 (0) ≥ 4 ≥ 4
Colistin 1 (0.6) 0 (0) 154 (99.4) ≤ 0.5 ≤ 0.5
R - resistant; I - intermediate susceptible; S - susceptible
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target for therapy with tigecycline is insufficient
(25). The results of susceptibility testing should be
reported as MIC values with a comment, but without
an accompanying S, I or R category (10). According
to some authors, the tigecycline MIC of A. bauman-
nii were also interpreted using EUCAST categories
for Enterobacteriaceae (susceptible, MIC = 1 mg/L;
resistant, MIC > 2 mg/L) (23, 25, 26).
Due to the lack of an international consensus
regarding tigecycline breakpoints for Acinetobacter
spp., the interpretation of results obtained in our
study was conducted using susceptibility break-
points for Enterobacteriaceae established by the
U.S. FDA and EUCAST recommendations, for
comparison purpose only.
Statistical analysis
Statistical analysis was performed to determine
the differences between the level of resistance to
tigecycline in the years 2008-2010 and 2011-2013
and between the criteria of FDA and EUCAST.
Statistical methods were also applied to compare the
resistance to tigecycline of the tested organisms iso-
lated from different clinical specimens. The Chi-
square test of Independence (χ2) alone or with
Yatesí correction (when expected values were less
than five), or Fisherís Exact test (two-sided) were
used to compare discrete variables. A p value less
than 0.05 was considered statistically significant.
All analyses were performed with StatsDirect, ver-
sion 2.7.9 (StatsDirect Ltd., Cheshire, UK).
Ethics statement
The present study does not require an approval
from the ethics committee.
RESULTS
A total of 155 A. baumannii strains, in accor-
dance with expert rules described by Magiorakos et
al. (5) were multidrug-resistant. Data detailing the
susceptibility to all tested antimicrobial agents
(except tigecycline) and the values of MIC50 and
MIC90 for A. baumannii strains isolated between
2008 and 2013, are shown in Table 1.
Colistin was the agent which displayed a good
activity (99.4% susceptible isolates) against tested
MDR strains, with MIC90 less than 0.5 mg/L, followed
by amikacin (39.4% susceptible isolates). Notably, in
our study the only isolate resistant to colistin was sus-
ceptible to tigecycline with MIC 2 mg/L. A high level
of carbapenem non-susceptibility was observed, with
92.9% and 91.0% of isolates resistant to meropenem
and imipenem, respectively. Ciprofloxacin and gen-
tamicin also should not be taken into account when
selecting the most appropriate antimicrobial therapy,
due to a high percentage of resistant strains, 100% and
89%, respectively (Table 1).
The distribution of tigecycline MIC values of
A. baumannii is shown in Figure 1. The MIC50 and
MIC90 values were 3 and 8 mg/L, respectively, with
a wide MIC range of tigecycline, from 0.125 to 48
mg/L. Forty (25.8%) of the isolates displayed MIC
= 2 mg/L and the MIC value most frequently
observed among the tested strains, was 3 mg/L
(23.2%).
MIC values for tigecycline were interpreted
according to breakpoints for Enterobacteriaceae set
by the FDA and EUCAST recommendations, for
comparison purposes only (Table 2). Using FDA
breakpoints it was found that 40 A. baumannii iso-
lates (25.8%) were susceptible to tigecycline, while
according to EUCAST interpretative criteria, only
17 strains (11.0%) were susceptible to this antimi-
crobial agent. On the basis of EUCAST breakpoints,
a high tigecycline resistance rate of 74.2% was
observed, when only 24.5% of isolates were resist-
ant according FDA interpretation-based category.
The percentage of non-susceptibility (resistant or
intermediate susceptible strains) was 74.2% and
89.0% with American and European recommenda-
tions, respectively. 
Table 2. Evaluation of Acinetobacter baumannii susceptibility to tigecycline according to EUCAST and FDA
breakpoints.
Recommendation
Interpretation of tigecycline MIC value EUCAST FDA
No. (%) of isolates No. (%) of isolates
Resistant 115 (74.2) 38 (24.5)
Intermediate susceptible 23 (14.8) 77 (49.7)
Susceptible 17 (11.0) 40 (25.8)
Total 155 (100.0) 155 (100.0)
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According to FDA interpretation, compared to
EUCAST rules, tigecycline-resistant strains of A.
baumannii occurred significantly less frequently in
the years 2008-2010 (p < 0.001; statistically signifi-
cant, Chi-square test of Independence) and 2011-
2013 (p < 0.001; statistically significant, Chi-square
test of Independence).
The FDA criteria were used to further analyse
the occurrence of tigecycline resistance among iso-
lates. The level of resistance to tigecycline has
changed over the years covered by the study. The
highest percentage of resistance among A. bauman-
nii strains was noted in 2010 (56.3%), followed by
2012 (50.0%) and 2013 (30.4%). Twenty-zero eight
was the year without confirmed resistant isolates
and in the years 2009 and 2011 we observed resist-
ance in 20.3% and 11.8% isolates, respectively.
The investigated period of time was divided
into the years 2008-2010 and 2011-2013, when 105
and 50 strains of A. baumannii were isolated.
Tigecycline resistance of A. baumannii strains in the
selected years was compared with the use of the χ2
test and an increase of resistance was demonstrated
from 22.8% in the years 2008-2010 to 28.0% in the
years 2011-2013, although statistically this relation-
ship was not significant (p = 0.487) (Table 3).
Chi-square test or Fisherís Exact test (two-
sided) were applied to compare the tigecycline
resistance levels of strains isolated from wound
swabs and other specimens. No statistically signifi-
cant difference (p = 0.05) in the tigecycline resist-
ance between isolates recovered from wound swabs
and strains cultured from other clinical materials
(ETA, p = 0.714; blood samples, p = 0.991; urine, p
= 0.523; catheter, p = 0.335) was observed.
DISCUSSION
Non-fastidious bacilli of the species A. bau-
mannii were the main cause of infections occurring
in patients of the Rydygier Memorial Specialized
Hospital in Krakow, Poland. Eighty six (55.5%)
patients of our studied group were admitted to the
intensive care unit, and endotracheal aspirates were
the specimens most often taken from those subjects.
It may have been associated with the development
of hospital-acquired pneumonia (data not available).
When a MDR A. baumannii strain was isolated and
other treatment options were limited or unavailable,
tigecycline may have been used off-label as a last-
resort medication (27). Several authors have also
reported the use of tigecycline in A. baumannii
infections of respiratory tract (VAP), blood (bac-
teremia) and other, in which this drug was not rec-
ommended (28-31).
For the first time, tigecycline was approved in
2005, and since then, the proposed scope of its
application has been extended. Moreover, it is a rel-
atively new antibacterial agent so future modifica-
tions or other changes in the recommendations for
its use may be necessary due to a growing body of
experience, results of new clinical trials, evolving
Figure 1. Distribution of tigecycline MIC values of Acinetobacter baumannii isolates (interpretation by FDA)
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epidemiological situation, and the increasing resist-
ance of clinically relevant pathogens.
Etest was considered as a reliable method of
tigecycline susceptibility testing (23, 32), although
some investigators revealed that MICs obtained by
this method were generally two- to fourfold higher
than broth microdilution MICs among selected bac-
terial species (A. baumannii, Serratia marcescens,
Streptococcus pneumoniae) (19). It is difficult to
pinpoint the factors that may be affecting suscepti-
bility testing performance against Acinetobacter
spp., however some researchers observed that a vari-
able concentration of manganese in Mueller Hinton
2 agar medium, used in Etest and disk diffusion
method, had an impact on the tigecycline MICs
against A. baumannii (10, 19).
Since the clinical breakpoints of tigecycline for
A. baumannii are not available, recommendations
for the use of this antibacterial agent are problemat-
ic. The lack of an international consensus and
reports of increasing resistance among A. baumannii
isolates are of growing concern (16, 33). Non-sus-
ceptibility to this glycylcycline was observed most
frequently in MDR A. baumannii and certain species
of the family Enterobacteriaceae (especially
Klebsiella pneumoniae, Escherichia coli, Entero-
bacter spp.) (34). 
Our study was restricted to the strains isolated
from patients of a single tertiary hospital, therefore
generalization to other clinical settings was limited.
Another drawback of this study was the absence of
molecular identification of isolates. Without isolate
genotyping, it was difficult to determine if regional
changes in MIC values were caused by local out-
breaks or widespread increases in resistance in the
general bacterial population (35). 
Interpretation of MICs for tigecycline accord-
ing to the European and American guidelines has
shown a higher percentage of resistant strains with
the EUCAST criteria, due to the more stringent
breakpoints. Zarkotou et al. (23), who had tested
tigecycline against 56 A. baumannii isolates by
Etest, also noted the higher rates of resistant strains
(17; 30.4% versus 6; 10.7%) and lower rates of sus-
ceptible isolates (16; 28.6% versus 39; 69.6%),
when the EUCAST rules were applied and com-
pared with FDA. In this Greek study, the MIC50 and
MIC90 of tigecycline for MDR A. baumannii were
reported to be 2 and 4 mg/L, respectively. Chen et
al. (36) in the ìTigecycline In Vitro Surveillanceî in
Taiwan, reported higher tigecycline resistance when
the EUCAST breakpoints were applied (31.9%
resistant strains for EUCAST criteria compared to
8.8% for FDA criteria). Liu et al. (26) obtained sim-
ilar results (39.4% compared to 9.9%, respectively).
Our conclusions were comparable to both groups.
Many authors based their interpretations of tigecy-
cline MICs for A. baumannii on the FDA
Enterobacteriaceae breakpoints (9, 30, 37, 38). The
comparison of our results with results of other inves-
tigators was also conducted on the basis of the FDA
criteria.
High rates of non-susceptibility to most antimi-
crobial agents of the first-line treatment options for
Acinetobacter infections were reported for the ana-
lyzed A. baumannii isolates. Tigecycline and col-
istin, antimicrobials commonly used in therapy, still
presented good activity against this microorganism
(11, 35). Our study revealed that colistin could be
the most appropriate regimen for the treatment of
Acinetobacter infections. Remarkably high tigecy-
cline non-susceptibility rates (74.2% according to
FDA criteria) of A. baumannii clinical isolates,
demonstrated in our study, suggest that tigecycline
may not be an option to treat A. baumannii infec-
tions. Ku and coworkers (34), who compared the
efficacy of colistin to tigecycline for the treatment of
A. baumannii infections, revealed that 82% of the
tested A. baumannii clinical isolates were non-sus-
ceptible to tigecycline. They pointed out that tigecy-
cline monotherapy should be limited to patients
without severe sepsis and that it was more common-
ly used for wound infections, than colistin (34). In
contrast, Eser et al. (29) observed potent tigecycline
in vitro activity (MIC90 1.5 mg/L) among 32 MDR A.
baumannii strains and its utility as a therapeutic
Table 3. Resistance to tigecycline among Acinetobacter baumannii strains.
Interpretative No. (%) of tigecycline-resistant A. baumannii strains
criteria 2008-2010 2011-2013 p value a
n = 105 n = 50
FDA 24 (22.8%) 14 (28%) 0.487 NS
a p value Chi-square test of Independence (χ2); p ≤ 0.05 was deemed statistically significant; NS - non significant.
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option in patients with respiratory infections.
Moreover, the study conducted by Anthony et al.
(14) revealed, that in the group of patients with tige-
cycline resistant strains the mortality rate was high-
er than in the group from whom susceptible isolates
were cultured. These data suggest that clinical out-
come can be predicted by the tigecycline MIC val-
ues for A. baumannii determined pretherapeutically.
There are many studies evaluating tigecycline sus-
ceptibility for A. baumannii strains. Our observa-
tions were different from those reported by other
investigators, who observed tigecycline non-suscep-
tibility in 50% of the MDR A. baumannii isolates in
Italy (30), 45.5% in Taiwan (39), and 44% in Turkey
(31). The studies on MDR A. baumannii conducted
in Italy and Egypt reported even lower non-suscep-
tibility rate to tigecycline of 27.5% and 26.8% iso-
lates, respectively (37, 38). 
Concerning the activity of tigecycline against
MDR A. baumannii isolates, our results (25.8%)
were similar to those reported by Navon-Venezia et
al. (28), who obtained 22.0% susceptibility and Sun
et al. (22), who noted 17.7% susceptibility, against
the tested isolates.
In addition, the MIC50 and MIC90 for tigecy-
cline (3 and 8 mg/L, respectively) were higher than
that previously reported by other authors (11, 18, 19,
40-42), lower than those reported by Navon-
Venezia et al (28) and similar to those obtained by
Mohamed and Youssef (38). 
The high MICs of tigecycline observed in our
study differed from the previous reports in which
Acinetobacter isolates were almost uniformly sus-
ceptible to tigecycline. It is worth noting that a Latin
American global surveillance study called T.E.S.T
(The Tigecycline Evaluation and Surveillance Trial)
revealed good activity of this agent against A. bau-
mannii, where 95.8% of the isolates displayed a
MIC ≤ 2 mg/L (MIC50 0.5 mg/L and MIC90 2 mg/L)
(43). Another study concerning Acinetobacter spp.
strains from 32 countries showed a high activity of
tigecycline which inhibited 97.0% of isolates at ≤ 2
mg/L (MIC50/90, 0.5/2 mg/L). Over 140 strains from
Poland, included in this investigation, demonstrated
MIC50/90, values as 1 and 2 mg/L, respectively (44).
In a recent study (global surveillance program SEN-
TRY), Sader and coworkers (2013) observed good
activity of tigecycline among meropenem-non-sus-
ceptible A. baumannii isolates (89.8% and 65.2% of
susceptible strains according FDA and EUCAST
criteria, respectively). 
The distribution of tigecycline MICs varied
according to the geographic region and even within
the regions (44). Discrepancies between the results
of various studies may be attributed to the use of dif-
ferent methods of antimicrobial susceptibility
assessment in either case, discordance between the
methods or to variations within the analyzed popu-
lation of isolates (e.g., a high percentage of clonal
strains reflecting local outbreaks in institutions or
cities).
The effectiveness of this glycylcycline alone or
in combination with other antimicrobials for the
treatment of MDR A. baumannii infections in criti-
cally ill patients is still uncertain, due to the lack of
large, well-controlled clinical trials and extended
clinical experience. The results of the present study,
along with reports of decreasing susceptibility to
tigecycline among Acinetobacter strains, suggest
that antimicrobial resistance should be monitored
through surveillance programs in order to detect the
local, regional, and national variations in resistance
patterns and to guide appropriate empirical antimi-
crobial therapy (6, 11). 
To conclude, our results suggest that tigecy-
cline may be of limited clinical utility for the treat-
ment of infections involving the MDR
Acinetobacter non-fermentative bacilli. Further
investigations of A. baumannii isolates are required
to assess the efficiency of tigecycline in the man-
agement of nosocomial infections caused by this
significant pathogen. Tigecycline should be used
with caution, together with monitoring of suscepti-
bility patterns in order to delay the emergence of
increased resistance in this bacteria (4, 23, 29, 43). 
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